Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies
  • Posted: 04/27/2004

Chemoprevention Trial for Men at High Risk for Prostate Cancer

Name of the Trial

Phase III Randomized Study of Selenium as Chemoprevention of Prostate Cancer in Patients with High-Grade Prostatic Intraepithelial Neoplasia (SWOG-S9917). See the protocol summary.

Principal Investigators

Dr. Jim Marshall, Southwest Oncology Group; Dr. David Jarrard, Eastern Cooperative Oncology Group; and Dr. William Robert Lee, Cancer and Leukemia Group B.

Dr. Jim Marshall
Dr. Jim Marshall
Principal Investigator

Why This Trial Is Important

Prostate cancer is an important source of morbidity and mortality among men in the industrialized world. High-grade prostatic intraepithelial neoplasia (HGPIN), a condition characterized by abnormal and uncontrolled growth of the ductal cells of the prostate, may be a precursor to prostate cancer.

Intake of the dietary supplement selenium is believed to protect against prostate cancer. Researchers are interested in determining whether a daily dose of selenium might prevent prostate cancer from developing among men with HGPIN.

“HGPIN is very likely a premalignant lesion for prostate cancer, so it is important to find a chemopreventive agent that will be effective for this high-risk group,” said Dr. Marshall. “Selenium supplementation shows promise, so we need to know if it might prevent HGPIN from developing into prostate cancer.”

Contact Information

This trial is no longer accepting new patients. To locate other clinical trials for prostate cancer, search the NCI's database of clinical trials or call the NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.

Published Results

Marshall JR, Sakr W, Wood D, et al.: Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 15 (8): 1479-84, 2006.[PUBMED Abstract]

Sakr WA, Faulkner JR, Wood D: Low rate of confirming prostate cancer on repeat biopsies following diagnosis of high grade prostatic intraepithelial neoplasia: preliminary analysis of Southwest Oncology Group study s9917. [Abstract] Proceedings of the American Association for Cancer Research 45: A-1333, 305, 2004.